|
Gene: NEK9 |
Gene summary for NEK9 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NEK9 | Gene ID | 91754 |
Gene name | NIMA related kinase 9 | |
Gene Alias | APUG | |
Cytomap | 14q24.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8TD19 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91754 | NEK9 | LZE2T | Human | Esophagus | ESCC | 8.70e-08 | 5.62e-01 | 0.082 |
91754 | NEK9 | LZE4T | Human | Esophagus | ESCC | 7.46e-19 | 4.12e-01 | 0.0811 |
91754 | NEK9 | LZE7T | Human | Esophagus | ESCC | 4.00e-03 | 2.89e-01 | 0.0667 |
91754 | NEK9 | LZE8T | Human | Esophagus | ESCC | 1.95e-02 | 1.66e-01 | 0.067 |
91754 | NEK9 | LZE20T | Human | Esophagus | ESCC | 8.47e-03 | 1.52e-01 | 0.0662 |
91754 | NEK9 | LZE24T | Human | Esophagus | ESCC | 9.44e-15 | 3.64e-01 | 0.0596 |
91754 | NEK9 | LZE6T | Human | Esophagus | ESCC | 3.13e-02 | 1.10e-01 | 0.0845 |
91754 | NEK9 | P1T-E | Human | Esophagus | ESCC | 6.93e-05 | 2.14e-01 | 0.0875 |
91754 | NEK9 | P2T-E | Human | Esophagus | ESCC | 2.05e-20 | 3.42e-01 | 0.1177 |
91754 | NEK9 | P4T-E | Human | Esophagus | ESCC | 1.31e-18 | 4.57e-01 | 0.1323 |
91754 | NEK9 | P5T-E | Human | Esophagus | ESCC | 1.47e-06 | 7.48e-02 | 0.1327 |
91754 | NEK9 | P8T-E | Human | Esophagus | ESCC | 3.90e-25 | 3.79e-01 | 0.0889 |
91754 | NEK9 | P9T-E | Human | Esophagus | ESCC | 6.60e-17 | 2.08e-01 | 0.1131 |
91754 | NEK9 | P10T-E | Human | Esophagus | ESCC | 2.44e-34 | 4.89e-01 | 0.116 |
91754 | NEK9 | P11T-E | Human | Esophagus | ESCC | 1.10e-09 | 3.95e-01 | 0.1426 |
91754 | NEK9 | P12T-E | Human | Esophagus | ESCC | 4.27e-27 | 4.53e-01 | 0.1122 |
91754 | NEK9 | P15T-E | Human | Esophagus | ESCC | 3.51e-30 | 6.76e-01 | 0.1149 |
91754 | NEK9 | P16T-E | Human | Esophagus | ESCC | 3.44e-16 | 3.13e-01 | 0.1153 |
91754 | NEK9 | P17T-E | Human | Esophagus | ESCC | 4.66e-03 | 2.08e-01 | 0.1278 |
91754 | NEK9 | P19T-E | Human | Esophagus | ESCC | 1.01e-02 | 2.05e-01 | 0.1662 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEK9 | SNV | Missense_Mutation | novel | c.1543N>A | p.Asp515Asn | p.D515N | Q8TD19 | protein_coding | tolerated(0.05) | benign(0.424) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
NEK9 | SNV | Missense_Mutation | novel | c.1357N>T | p.Asp453Tyr | p.D453Y | Q8TD19 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
NEK9 | SNV | Missense_Mutation | novel | c.2486N>A | p.Ser829Tyr | p.S829Y | Q8TD19 | protein_coding | deleterious_low_confidence(0.05) | benign(0.006) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
NEK9 | SNV | Missense_Mutation | c.1080G>T | p.Gln360His | p.Q360H | Q8TD19 | protein_coding | tolerated(0.16) | benign(0.067) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
NEK9 | SNV | Missense_Mutation | c.2167A>G | p.Ile723Val | p.I723V | Q8TD19 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-B5-A0K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
NEK9 | SNV | Missense_Mutation | c.1522N>A | p.Glu508Lys | p.E508K | Q8TD19 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NEK9 | SNV | Missense_Mutation | novel | c.347N>C | p.Asn116Thr | p.N116T | Q8TD19 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NEK9 | SNV | Missense_Mutation | novel | c.2002N>A | p.Asp668Asn | p.D668N | Q8TD19 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
NEK9 | SNV | Missense_Mutation | c.2137N>A | p.Leu713Met | p.L713M | Q8TD19 | protein_coding | tolerated(0.12) | probably_damaging(0.994) | TCGA-D1-A101-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NEK9 | SNV | Missense_Mutation | novel | c.2803N>A | p.Glu935Lys | p.E935K | Q8TD19 | protein_coding | deleterious_low_confidence(0.05) | benign(0.055) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |